This brand name is authorized in France, Japan, New Zealand.
The drug DROLEPTAN contains one active pharmaceutical ingredient (API):
1
|
UNII
O9U0F09D5X - DROPERIDOL
|
|
Droperidol is a butyrophenone neuroleptic. Its pharmacologic profile is characterised mainly by dopamine-blocking and weak α1-adrenolytic effects. Droperidol is devoid of anticholinergic and antihistaminic activity. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| N05AD08 | Droperidol | N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AD Butyrophenone derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| FR | Base de données publique des médicaments | 61646847 |
| JP | 医薬品医療機器総合機構 | 1119401A1036 |
| NZ | Medicines and Medical Devices Safety Authority | 696, 698 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.